Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 16/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
| ▸ | KHK | P50053 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622722 | 0.93 | FFAR4 (0.43) | FFAR4 | |
| SCHEMBL1025565 | 0.83 | SCD (0.36) | FFAR4 | |
| Trifluoroacetic Acid SCHEMBL4354307 | 0.78 | FFAR4 (0.46) | FFAR4CYP3A4TACR1 | |
| Trifluoroacetic Acid SCHEMBL1026170 | 0.78 | FFAR4 (0.59) | FFAR4CYP3A4TACR1 | |
| Trifluoroacetic Acid SCHEMBL1026901 | 0.75 | FFAR4 (0.51) | FFAR4 | |
| Acetic Acid SCHEMBL1025767 | 0.75 | SCD (0.44) | — | |
| SCHEMBL4336905 | 0.74 | KMT2A (0.53) | — | |
| Trifluoroacetic Acid SCHEMBL1024329 | 0.73 | ALDH1A1 (0.55) | FFAR4CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL1023388 | 0.73 | DPP4 (0.53) | FFAR4 | |
| Trifluoroacetic Acid SCHEMBL1025547 | 0.72 | FFAR1 (0.50) | FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | FFAR4 2075/4885CYP3A4 3025/4885TACR1 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.